LV-320 NEW
| Price | $1430 | $1860 | $2675 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: LV-320 | CAS No.: 2449093-46-1 |
| Supply Ability: 10g | Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | LV-320 |
| Description | LV-320 is a potent, uncompetitive ATG4B inhibitor with an IC50 of 24.5 μM and a Kd of 16 μM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic, and active in vivo. These findings suggest that LV-320 will serve as a relevant chemical tool to study the various roles of ATG4B in cancer and other contexts [1]. |
| In vitro | LV-320 (0-120 μM; SKBR3, MCF7, JIMT1, and MDA-MB-231 cells) treatment leads to a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines [1]. LV-320 (120 μM; 48 hours; MDA-MB-231 cells) treatment results in an increase in LC3B-II, indicating that LV-320 blocks autophagic flux [1]. Western Blot Analysis [1] Cell Line: SKBR3, MCF7, JIMT1, and MDA-MB-231 cells Concentration: 0 μM, 25 μM, 50 μM, 75 μM, 100 μM, or 120 μM Incubation Time: Result: Resulted in a dose-dependent increase in endogenous LC3B-II and protein p62 levels in all four cell lines. Cell Autophagy Assay [1] Cell Line: MDA-MB-231 cells Concentration: 120 μM Incubation Time: 48 hours Result: Blocked autophagic flux. |
| In vivo | Administering LV-320 (100-200 mg/kg; oral gavage; three times over two days; GFP-LC3 mice) resulted in terminal blood and liver concentrations of 169 μM and 104 μM, respectively. This treatment significantly increased the accumulation of GFP-LC3 puncta and elevated LC3B-II protein levels in treated animals compared to controls, without causing notable toxicity at either dose [1]. The study utilized female GFP-LC3 mice aged 9-14 weeks [1], exploring the pharmacokinetics and the biological impact of LV-320 on autophagy-related markers. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 135 mg/mL (259.56 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (6.34 mM), Sonication is recommended. |
| Keywords | LV-320 | LV320 | LV 320 | CysteineProtease | Cysteine Protease | ATG4B |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $30.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-12 | |
|
VIP7Y
|
QINGDAO JADE NEW MATERIAL TECNOLOGY CO.,LTD
|
2026-06-02 | ||
| $2675.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-28 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY